nach oben

Journal of Bone and Mineral Metabolism

Erschienen in:

01.07.2012 | Review article

Menin and bone metabolism

verfasst von: Hiroshi Kaji

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Menin, a product of the MEN1 gene, is related to the ontogeny of several cancers such as MEN1 and sporadic endocrine tumors, although it is considered to be a tumor suppressor. Many proteins interact with menin, and it is involved in various biological functions in several tissues. Menin plays some physiological and pathological roles related to transforming growth factor-beta (TGF-β) signaling pathway in the parathyroid, and it is implicated in the tumorigenesis of parathyroid tumors. In bone, the bone phenotype was observed in some menin-deleted mice. Menin is considered to support BMP-2- and Runx2-induced differentiation of mesenchymal cells into osteoblasts by interacting with Smad1/5, Runx2, β-catenin and LEF-1, although it has different effects on osteoblasts at later differentiation stages through TGF-β-Smad3 and AP-1 pathways. Further research is expected to shed more light on the role of menin in bone.

Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS et al (1997) Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276:404–407

Thakker RV (2010) Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab 24:355–370PubMed

Guru SC, Goldsmith PK, Burns AL, Marx SJ, Spiegel AM, Collins FS, Chandrasekharappa SC (1998) Menin, the product of the MEN1 gene, is a nuclear protein. Proc Natl Acad Sci USA 95:1630–1634PubMed

Kaji H, Canaff L, Goltzman D, Hendy GN (1999) Cell cycle regulation of menin expression. Cancer Res 59:5097–5101PubMed

Hendy GN, Kaji H, Sowa H, Lebrun JJ, Canaff L (2005) Menin and TGF-β superfamily member signaling via the Smad pathway in pituitary, parathyroid and osteoblast. Horm Metab Res 37:375–379PubMed

Hendy GN, Kaji H, Canaff L (2009) Cellular functions of menin. Adv Exp Med Biol 668:37–50PubMed

Kaji H, Canaff L, Hendy GN (2009) Role of menin in bone development. Adv Exp Med Biol 668:59–67PubMed

Kaji H, Canaff L, Lebrun JJ, Goltzman D, Hendy GN (2001) Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type β signaling. Proc Natl Acad Sci USA 98:3837–3842PubMed

Hata A (2001) TGF-β signaling and cancer. Exp Cell Res 264:111–116PubMed

10.

Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Hofler H, Fend F, Graw J, Atkinson MJ (2006) Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 103:15558–15563PubMed

11.

Agarwal SK, Mateo CM, Marx SJ (2009) Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab 94:1826–1834PubMed

12.

Milne TA, Hughes CM, Lloyd R, Yang Z, Rozenblatt-Rosen O, Dou Y, Schnepp RW, Krankel C, Livolsi VA, Gibbs D, Hua X, Roeder RG, Meyerson M, Hess JL (2005) Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci USA 102:749–754PubMed

13.

Scappaticci S, Maraschio P, del Ciotto N, Fossati GS, Zonta A, Fraccaro M (1991) Chromosome abnormalities in lymphocytes and fibroblasts of subjects with multiple endocrine neoplasia type 1. Cancer Genet Cytogenet 52:85–92PubMed

14.

Jin S, Mao H, Schnepp RW, Sykes SM, Silva AC, D’Andrea AD, Hua X (2003) Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res 63:4204–4210PubMed

15.

Busygina V, Kottemann MC, Scott KL, Plon SE, Bale AE (2006) Multiple endocrine neoplasia type 1 interacts with forkhead transcription factor CHES1 in DNA damage response. Cancer Res 66:8397–8403PubMed

16.

Busygina V, Suphapeetiporn K, Marek LR, Stowers RS, Xu T, Bale AE (2004) Hypermutability in a Drosophila model for multiple endocrine neoplasia type 1. Hum Mol Genet 13:2399–2408PubMed

17.

Hessman O, Skogseid B, Westin G, Akerström G (2001) Multiple allelic deletions and intratumoral genetic heterogeneity in men1 pancreatic tumors. J Clin Endocrinol Metab 86:1355–1361PubMed

18.

Shen HC, He M, Powell A, Adem A, Lorang D, Heller C, Grover AC, Ylaya K, Hewitt SM, Marx SJ, Spiegel AM, Libutti SK (2009) Recapitulation of pancreatic neuroendocrine tumors in human multiple endocrine neoplasia type 1 syndrome via Pdx1-directed inactivation of Men1. Cancer Res 69:1858–1866PubMed

19.

Hsi E, Zukerberg LR, Yang WI, Arnold A (1996) Cyclin D1 (PRAD1) expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab 81:1736–1739PubMed

20.

Imanishi Y, Hosokawa Y, Yoshimoto K, Schipani E, Mallya S, Papanikolaou A, Kifor O, Tokura T, Sablosky M, Ledgard F, Gronowicz G, Wang TC, Schmidt EV, Hall C, Brown EM, Bronson R, Arnold A (2001) Primary hyperparathyroidism caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J Clin Invest 107:1093–1102PubMed

21.

Dotzenrath C, Teh BT, Farnebo F, Cupisti K, Svensson A, Toell A, Goretzki P, Larsson C (1996) Allelic loss of the retinoblastoma tumor suppressor gene: a marker for aggressive parathyroid tumors? J Clin Endocrinol Metab 81:3194–3196PubMed

22.

Juhlin CC, Nilsson IL, Johansson K, Haglund F, Villablanca A, Höög A, Larsson C (2010) Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. Endocr Pathol 21:166–177PubMed

23.

Heppner C, Kester MB, Agarwal SK, Debelenko LV, Emmert-Buck MR et al (1997) Somatic mutation of the MEN1 gene in parathyroid tumors. Nat Genet 16:375–378

24.

Crabtree JS, Scacheri PC, Ward JM, Garrett-Beal L, Emmert-Buck MR, Edgemon KA, Lorang D, Libutti SK, Chandrasekharappa SC, Marx SJ, Spiegel AM, Collins FS (2001) Characterization of the mouse Men1 gene and its expression during development. Proc Natl Acad Sci USA 17:2485–2493

25.

Libutti SK, Crabtree JS, Lorang D, Burns AL, Mazzanti C, Hewitt SM, O’Connor S, Ward JM, Emmert-Buck MR, Remaley A, Miller M, Turner E, Alexander HR, Arnold A, Marx SJ, Collins FS, Spiegel AM (2003) Parathyroid gland-specific deletion of the mouse Men1 gene results in parathyroid neoplasia and hypercalcemic hyperparathyroidism. Cancer Res 63:8022–8028PubMed

26.

Sowa H, Kaji H, Kitazawa R, Kitazawa S, Tsukamoto T, Yano S, Tsukada T, Canaff L, Hendy GN, Sugimoto T, Chihara K (2004) Menin inactivation leads to loss of transforming growth factor β inhibition of parathyroid cell proliferation and parathyroid hormone secretion. Cancer Res 64:2222–2228PubMed

27.

Naito J, Kaji H, Sowa H, Kitazawa R, Kitazawa S, Tsukada T, Hendy GN, Sugimoto T, Chihara K (2006) Expression and functional analysis of menin in a multiple endocrine neoplasia type 1 (MEN1) patient with somatic loss of heterozygosity in chromosome 11q13 and unidentified germline mutation of the MEN1 gene. Endocrine 29:485–490PubMed

28.

Sayo Y, Murao K, Imachi H, Cao WM, Sato M, Dobashi H, Wong NC, Ishida T (2002) The multiple endocrine neoplasia type 1 gene product, menin, inhibits insulin production in rat insulinoma cells. Endocrinology 143:2437–2440PubMed

29.

Namihira H, Sato M, Murao K, Cao WM, Matsubara S, Imachi H, Niimi M, Dobashi H, Wong NC, Ishida T (2002) The multiple endocrine neoplasia type 1 gene product, menin, inhibits the human prolactin promoter activity. J Mol Endocrinol 29:297–304PubMed

30.

Karnik SK, Chen H, McLean GW, Heit JJ, Gu X, Zhang AY, Fontaine M, Yen MH, Kim SK (2007) Menin controls growth of pancreatic β-cells in pregnant mice and promotes gestational diabetes mellitus. Science 318:806–809PubMed

31.

Stewart C, Parente F, Piehl F, Farnebo F, Quincey D et al (1998) Characterization of the mouse Men1 gene and its expression during development. Oncogene 17:2485–2493

32.

Deng ZL, Sharff KA, Tang N, Song WX, Luo J, Luo X, Chen J, Bennett E, Reid R, Manning D, Xue A, Montag AG, Luu HH, Haydon RC, He TC (2008) Regulation of osteogenic differentiation during skeletal development. Front Biosci 13:2001–2021PubMed

33.

Sowa H, Kaji H, Yamaguchi T, Sugimoto T, Chihara K (2002) Smad3 promotes alkaline phosphatase activity and mineralization of osteoblastic MC3T3-E1 cells. J Bone Miner Res 17:1190–1199PubMed

34.

Inoue Y, Canaff L, Hendy GN, Hisa I, Sugimoto T, Chihara K, Kaji H (2009) Role of Smad3, acting independently of transforming growth factor-β, in the early induction of Wnt-β-catenin signaling by parathyroid hormone in mouse osteoblastic cells. J Cell Biochem 108:285–294PubMed

35.

Sowa H, Kaji H, Canaff L, Hendy GN, Tsukamoto T, Yamaguchi T, Miyazono K, Sugimoto T, Chihara K (2003) Inactivation of menin, the product of the multiple endocrine neoplasia type 1 gene, inhibits the commitment of multipotential mesenchymal stem cells into the osteoblast lineage. J Biol Chem 278:21058–21069PubMed

36.

Sowa H, Kaji H, Hendy GN, Canaff L, Komori T, Sugimoto T, Chiahra K (2004) Menin is required for bone morphogenetic protein2- and transforming growth factor-β-regulated osteoblastic differentiation through interaction with Smads and Runx2. J Biol Chem 279:40267–40275PubMed

37.

Aziz A, Miyake T, Engleka KA, Epstein JA, McDermott JC (2009) Menin expression modulates mesenchymal cell commitment to the myogenic and osteogenic lineages. Dev Biol 332:116–130PubMed

38.

Dreijerink KMA, Varier RA, van Beekum O, Jeninga EH, Hoppner JWM, Lips CJM, Kummer JA, Kalkhoven E, Timmers HTM (2009) The multiple endocrine neoplasia type 1 (MEN1) tumor suppressor regulates peroxisome proliferator-activated receptor γ-dependent adipocyte differentiation. Mol Cell Biol 29:5060–5069PubMed

39.

Agarwal SK, Guru SC, Heppner C, Erdos MR, Collins RM, Park SY, Saggar S, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ, Burns AL (1999) Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 96:143–152PubMed

40.

Kim H, Lee JE, Cho EJ, Liu JO, Youn HD (2003) Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A–histone deacetylase complex. Cancer Res 63:6135–6139PubMed

41.

Agarwal SK, Novotny EA, Crabtree JS, Witzman JB, Yaniv M, Burns AL, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ (2003) Transcription factor JunD, deprived of menin, switches from growth suppressor to growth promoter. Proc Natl Acad Sci USA 100:10770–10775PubMed

42.

Naito J, Kaji H, Sowa H, Hendy GN, Sugimoto T, Chihara K (2005) Menin suppresses osteoblast differentiation by antagonizing the AP-1 factor, JunD. J Biol Chem 280:4785–4791PubMed

43.

Tobimatsu T, Kaji H, Sowa H, Naito J, Canaff L, Hendy GN, Sugimoto T, Chihara K (2006) Parathyroid hormone increases β-catenin levels through Smad3 in mouse osteoblastic cells. Endocrinology 147:2583–2590PubMed

44.

Hisa I, Inoue Y, Hendy GN, Canaff L, Kitazawa R, Kitazawa S, Komori T, Sugimoto T, Seino S, Kaji H (2011) Parathyroid hormone-responsive Smad3-related factor, Tmem119, promotes osteoblast differentiation and interacts with the bone morphogenetic protein-Runx2 pathway. J Biol Chem 286:9787–9796PubMed

45.

Rowadi G, Vayssiere B, Dunn F, Baron R, Roman-Roman S (2003) BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 18:1842–1853

46.

Chen Y, Whetstone HC, Youn A, Nudesan P, Chow EC, Lin AC, Alman BA (2007) β-Catenin signaling pathway is crucial for bone morphogenetic protein 2 to induce new bone formation. J Biol Chem 282:526–533PubMed

47.

Inoue Y, Hendy GN, Canaff L, Seino S, Kaji H (2011) Menin interacts with β-catenin in osteoblast differentiation. Horm Metab Res 43:183–187PubMed

48.

Chen G, Jingbo AJ, Wang M, Farley S, Lee LC, Sawicki MP (2008) Menin promotes the Wnt signaling pathway in pancreatic endocrine cells. Mol Cancer Res 6:1894–1907PubMed

49.

Cao Y, Liu R, Jiang X, Lu J, Jiang J, Zhang C, Li X, Ning G (2009) Nuclear-cytoplasmic shuttling of menin regulates translocation of β-catenin. Mol Cell Biol 29:5477–5487PubMed

50.

Bertolino P, Tong WM, Herrerra PL, Casse H, Zhang CX, Wang ZQ (2003) Pancreatic β-cell specific ablation of the multiple endocrine neoplasia type 1 (MEN1) gene causes full penetrance of insulinoma development in mice. Cancer Res 63:4836–4841PubMed

51.

Lin SY, Elledge SJ (2003) Multiple tumor suppressor pathways negatively regulate telomerase. Cell 113:881–889PubMed

52.

Maillard I, Chen YX, Friedman A, Yang Y, Tubbs AT, Shestova O, Pear WS, Hua X (2009) Menin regulates the function of hematopoietic stem cells and lymphoid progenitors. Blood 113:1661–1669PubMed

53.

van Kesteren RE, Syed NI, Munno DW, Bouwman J, Feng ZP, Geraerts WPM, Smit AB (2001) Synapse formation between central neurons requires postsynaptic expression of the MEN1 tumor suppressor gene. J Neurosci 21:RC161

54.

Cheng P, Yang SS, Hu XG, Zhou XY, Zhang YJ, Zhang YJ, Jin YJ, Zhou YQ (2011) Menin prevents liver steatosis through co-activation of peroxisome proliferator-activated receptor alpha. FEBS Lett 585:3403–3408PubMed

55.

Engleka KA, Wu M, Zhang M, Antonucci NB, Epstein JA (2007) Menin is required in cranial neural crest for palatogenesis and perinatal viability. Dev Biol 311:524–537PubMed

56.

Kanazawa I, Nayak G, Canaff L, Murshed M, Hendy GN (2011) Reduced accumulation of bone in mice lacking the Men1 gene in osteoblasts. J Bone Miner Res 26:s309

57.

Loffler KA, Biondi CA, Gartside MG, Serewko-Auret MM, Duncan R, Tonks ID, Mould AW, Waring P, Muller HK, Kay GF, Hayward NK (2007) Lack of augmentation of tumor spectrum or severity in dual heterozygous Men1 and Rb1 knockout mice. Oncogene 26:4009–4017PubMed

58.

Dreijerink KM, Mulder KW, Winkler GS, Höppener JW, Lips CJ, Timmers HT (2006) Menin links estrogen receptor activation to histone H3K4 trimethylation. Cancer Res 66:4929–4935PubMed

59.

Chen YX, Yan J, Keeshan K, Tubbs AT, Wang H, Silva A, Brown EJ, Hess JL, Pear WS, Hua X (2006) The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. Proc Natl Acad Sci USA 103:1018–1023PubMed

60.

Hughes CM, Rozenblatt-Rosen O, Milne TA, Copeland TD, Levine SS, Lee JC, Hayes DN, Shanmugam KS, Bhattacharjee A, Biondi CA, Kay GF, Hayward NK, Hess JL, Meyerson M (2004) Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell 13:587–597PubMed

61.

La P, Schnepp RW, Petersen CD, C Silva A, Hua X (2004) Tumor suppressor menin regulates expression of insulin-like growth factor binding protein 2. Endocrinology 145:3443–3450PubMed

Titel: Menin and bone metabolism
verfasst von: Hiroshi Kaji
Publikationsdatum: 01.07.2012
Verlag: Springer Japan
Erschienen in: Journal of Bone and Mineral Metabolism / Ausgabe 4/2012
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-012-0355-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Effect of hyperlipidemia on femoral biomechanics and morphology in low-density lipoprotein receptor gene knockout mice

Asymptomatic Paget’s bone disease in ethnic Thais: a series of four case reports and a review of the literature

A study of changes in bone metabolism in cases of gender identity disorder

Sexual dimorphism of femoral neck cross-sectional bone geometry in athletes and non-athletes: a hip structural analysis study

Effect of Escherichia coli-produced recombinant human bone morphogenetic protein 2 on the regeneration of canine segmental ulnar defects